Articles tagged with Cancer Medication
A team of researchers discovered non-coding RNA molecules in cancer cells that stimulate an immune response by mimicking pathogens. The findings suggest these molecules may play a significant role in mediating immune responses against cancer.
A mindfulness-based stress reduction program has been shown to improve attention and reduce mistakes on difficult cognitive tasks in breast and colorectal cancer survivors. The program, known as MBSR, provides a creative solution for managing cancer-related cognitive impairment, which can be incapacitating.
The Target Validation Platform provides a single, robust infrastructure that integrates high-level information from key sources of evidence. It enables communities to work together, making the hand-off from basic research to drug discovery smoother, and is expected to grow substantially as it integrates experimental project data.
A study of 87 CLL patients found 12 genetic mutations that can be targeted by therapies already available for other cancers, including PARP and BRAF inhibitors. These mutations were detected through next-generation sequencing and may offer new treatment options for patients who fail current therapies.
A multi-center study found ibrutinib to be more effective than chlorambucil in treating CLL, with a 97.8% overall survival rate after two years compared to 85.3%. Ibrutinib also improves hemoglobin and platelet levels.
A SWOG trial shows that adding bortezomib to lenalidomide and dexamethasone therapy in early treatment improves remission time and life expectancy for myeloma patients by about a year, compared to the standard two-drug regime.
Scientists create virtual tumors to test drug treatments, achieving an 85-86% correlation with lab results. The goal is a patient-specific workflow for early diagnosis and effective treatment identification.
Researchers analyzed canine cell lines to understand cancer development and metastasis, identifying key gene switches that could be targeted with novel therapeutics. The study provides a basis for further research into personalized medicine for dogs with cancer.
The Beat AML collaboration has identified over 10 cell signaling pathways and mutations that may contribute to disease progression in acute myeloid leukemia. Researchers have also found promising therapeutic approaches, including disrupting the cancer cell microenvironment and targeting key inflammatory pathways.
A study published in The Lancet Oncology reveals that cancer drug prices vary significantly between European countries, with some nations paying up to 388% more than others for the same medication. The UK and Mediterranean countries have the lowest average unit manufacturer prices for a group of 31 originator cancer drugs, while German...
A new study published in Annals of Oncology shows that abiraterone acetate is effective in treating aggressive prostate cancers, even those with high Gleason scores. The treatment extended progression-free survival by up to 16.5 months in patients previously treated with docetaxel.
Researchers from Sylvester Comprehensive Cancer Center are presenting their latest hematology research at the American Society of Hematology (ASH) Annual Meeting. Highlights include the discovery of a potent inhibitor of Lysine demethylase Lsd-1, which augments pro-differentiation effects in acute myeloid leukemia (AML), and targeting ...
Researchers at UC San Diego School of Medicine discovered a specific group of proteins decrease, triggering changes in the cancer microenvironment and accelerating growth of therapy-resistant CSCs. A targeted monoclonal antibody treatment effectively impaired CSC regeneration and made them easier to target with existing therapies.
A team of researchers discovered how a new anti-leukemia drug, JQ1, works by inhibiting BRD4 and causing the NSD3-short protein to 'fly apart', disrupting cancer cell growth. The NSD3-short protein acts as an adaptor protein, coupling BRD4 to CHD8, and has four distinct functions necessary for AML cells to thrive.
The study found that prices for all surveyed classes of brand-name drugs increased by an average of 401%, with topical antineoplastic drugs experiencing the largest percentage increase at 1240%. Psoriasis medications had the smallest average percentage increase, rising by just 180%.
Scientists have mapped out the human genome to identify essential genes for cell survival, revealing a core set of over 1,500 genes. The findings suggest that each tumor relies on a unique set of genes that can be targeted by specific drugs, offering hope for devising new treatments.
The latest Special Issue in ecancermedicalscience explores the intersection of biomarkers, screening and prevention using pharmaceutical agents. Researchers discuss validated biomarkers, chemoprevention and its challenges, as well as innovative approaches like circulating free-micro RNAs and circulating tumour DNA.
A preclinical study finds that AR-42, an HDAC inhibitor, preserves muscle health and function while stopping life-threatening muscle wasting associated with advanced cancers. The experimental agent was shown to have a strong protective effect against tumor-associated muscle wasting in two preclinical models.
Immune cells called Langerhans cells can uniquely repair DNA damage caused by radiotherapy, making them resistant to treatment. Researchers found that mimicking immunotherapy drugs can block this ability, preventing immune response and improving radiation therapy effectiveness.
A team of U of T engineers has developed a way to grow cancer cells in the form of a rolled-up sheet that mimics the 3D environment of a tumour, offering a way to speed up drug development and ask new questions about cell behavior. The single-layer design makes it easier for other lab researchers to adopt the process.
Researchers found p53 blocks PDL1 protein, which halts immune attack on lung cancer cells. High levels of p53 and miR-34a increase survival rates in patients with lung cancer.
Health experts argue that pharmaceutical companies abuse the Orphan Drug Act by marketing drugs for common conditions, generating billions in profits. The law was designed to encourage rare disease treatments but has instead led to high medication costs and monopolies.
A recent study by Georgetown University researchers reveals that wheelchair users are approximately 36% more likely to die in road traffic collisions. The majority of fatal crashes occurred at intersections with poor pedestrian infrastructure, indicating the need for improved accessibility and safety measures.
A new personalized method for testing drug effectiveness in multiple myeloma predicts the best treatments for individual patients. The test suggests commonly prescribed drugs or combination therapies, as well as optimal dosages.
Researchers at Brigham Young University create a system to speed up vaccine production by storing the biological machinery in a freeze-dried state. This allows labs to rapidly produce vaccines with just the addition of water, reducing the time from months to days.
A University of Colorado Cancer Center study shows that breast cancer patients without prescription drug coverage are less likely to start and continue hormonal therapy due to high costs. Women from lower-income households were particularly affected, highlighting the need for affordable prescription coverage.
A broad-spectrum approach to cancer treatment and prevention is being developed by researchers, focusing on low-toxicity agents from plants and foods that target multiple pathways involved in cancer development. The approach aims to improve upon current targeted therapies and reduce costs associated with toxicity and treatment duration.
A new study funded by The Ben & Catherine Ivy Foundation has identified propentofylline as a potential drug that could help treat glioblastoma multiforme (GBM), a deadly brain tumor. The research found that PPF can limit the spread of GBM and increase the effectiveness of chemotherapy drugs and radiation therapy.
A new study by Oregon State University reveals that rural residents aged 85 or older have higher levels of chronic disease, take more medications, and die earlier than their urban counterparts. The research highlights the challenges faced by older populations in rural areas due to limited access to healthcare services.
A study at MD Anderson Cancer Center found that suppressing epithelial-to-mesenchymal transition (EMT) in combination with gemcitabine may boost the drug's effectiveness against pancreatic cancer. EMT suppression leads to impaired sensitivity to chemotherapy, causing poor prognosis and metastasis.
A new blood test can detect when breast cancers become resistant to standard hormone treatment, allowing for early identification and alternative treatment options. Researchers developed the test to identify ESR1 mutations, which convey resistance to hormone treatment.
Researchers discover a link between colorectal cancer and melanoma treatment NT157, targeting both tumor cells and microenvironment to suppress cancer growth. The compound's dual mechanism of action shows promise in treating colon cancer with minimal damage to non-cancer cells.
A new study suggests that rare 'missense' mutations in the HER2 gene may not cause breast cancer growth or spread on their own. The research team found that such mutations may also fail to predict response to anti-cancer drugs targeting the HER2 gene, unlike common amplification alterations.
Researchers have discovered a new genetic cause of childhood kidney cancer, Wilms tumour, linked to mutations in the REST gene. The study found that REST mutations occur in about 10% of familial cases and can be detected through simple blood tests, providing valuable information for families affected by the disease.
Researchers at Temple University Health System have discovered a small molecule inhibitor that selectively kills cancer cells with BRCA1 or BRCA2 gene mutations. The compound, 6-hydroxy-DL-dopa, works by blocking an alternative DNA repair pathway, providing a promising approach to precision medicine for various cancers.
Experts discuss the impact of affordable medicines on breast cancer treatment, highlighting the importance of healthcare structures in improving patient outcomes. The lack of effective systems can negate even new, expensive treatments.
Researchers have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug. The test predicts which patients will not respond to treatment and can inform personalized treatment options.
Australian scientists identified a critical molecular feedback loop in neuroblastoma that accelerates cancer development. Experimental drug CBL0137 has the potential to interrupt this loop and halt tumour progression, showing promising results in laboratory models.
A BU School of Medicine researcher has identified a small molecule that selectively kills ALT-positive cancer cells, offering a potential therapeutic approach to deadly forms of human cancer. The discovery targets the ALT pathway, frequently reactivated in aggressive cancers such as osteosarcoma and glioblastoma.
A new study found that breast cancer adjuvant therapies have varying effects on patients over time. Researchers analyzed 19 clinical trials and discovered nearly half showed time-varying treatment effects.
A study published in JAMA Dermatology found that a common heart medication can stop the progression of angiosarcoma, a highly lethal blood vessel cancer. The treatment used propranolol, which costs significantly less than current therapies.
A recent study found that antiangiogenic breast cancer treatment primarily benefits patients with highly perfused tumors. The treatment reduced pressure within tumors and improved blood vessel density, but its effectiveness depends on the tumor's microvascular density before treatment.
Researchers at University of Oxford have discovered a new treatment targeting cancer cells with specific SETD2 mutations. The innovative approach uses a drug inhibiting WEE1 protein, exploiting synthetic lethality to selectively kill cancer cells.
New liposome technology allows for targeted delivery of cancer drugs, using heat-activated triggers to control release. This innovative approach could reduce collateral damage and improve treatment efficacy.
Dr. Emily Scott's work focuses on understanding how cytochrome P450s remove foreign chemicals from the body, allowing physicians to determine optimal medication frequencies and prevent diseases like cancer. Her lab is now working to stabilize interactions between P450s and helper proteins.
Researchers have discovered a genomic molecular fingerprint, signature 3, that highlights certain gastric cancers susceptible to treatment with platinum drugs or PARP inhibitor drugs. This biomarker could guide targeted therapy for breast, ovarian and pancreatic cancers as well.
The new approach uses a single chemical compound that makes cancer cells glow when exposed to near-infrared light, allowing for more effective removal of tumors. In laboratory tests, tumors were completely eradicated without side effects, and the treatment showed promise in targeting specific cancers.
A study published in JAMA Oncology found that superlatives like 'breakthrough' and 'miracle' were used to describe unapproved cancer drugs, often without clinical data. Targeted therapy was the most commonly referenced class of drugs, with immunologic checkpoint inhibitors also being frequently described as 'game-changers'.
Franziska Michor is awarded the NYSCF -- Robertson Stem Cell Prize for her interdisciplinary research on cancer genesis, using mathematical models to understand cancer evolution. Her work simulates drug treatment regimens and has been tested in clinical trials for non-small-cell lung cancer and brain tumors.
A new clinical trial has shown that a gene-targeted drug, olaparib, can benefit up to 33% of patients with treatment-resistant advanced prostate cancer. The trial found that men whose tumours had defects in DNA repair machinery responded particularly well to the drug.
A retrospective survival analysis of 229 patients with late-stage cancer found that those who received methylnaltrexone lived twice as long and had fewer tumor progression reports compared to placebo groups. The study suggests methylnaltrexone may play a role in cancer therapy, but the exact mechanism is unclear.
Researchers discovered a protein called Zmiz1 that sticks to the Notch gene, triggering its cancer function. Deleting Zmiz1 from Notch eliminates the cancer effect while preserving normal health functions.
PharmaMar presents new studies on the treatment of ovarian cancer using YONDELIS (trabectedin) and PM1183, showing promising results in managing recurrent cancer. The studies highlight the potential benefits of combining these therapies to improve patient outcomes.
Researchers have discovered molecular changes within tumors that prevent immunotherapy drugs from killing off cancer cells. By reprogramming an epigenetic mechanism, the therapy might work for more patients, according to senior author Weiping Zou.
Researchers have discovered a new combination of drugs that may be effective against resistant, BRAF-mutant melanoma by targeting different signaling pathways. The combination showed synergistic effects in tumors resistant to BRAF inhibition.
Scientists have created a highly specific chemical probe that switches off two important proteins implicated in cancer cell proliferation. The probe, CCT251545, selectively binds to CDK8 and CDK19, blocking the WNT signalling pathway and providing new insights into their role in driving cancer growth.
This special issue examines cancer screening, treatment, survivorship, access to care, and global health. Research articles investigate colorectal cancer screening, patient perceptions of stool DNA-based testing, financial barriers to specialty care for uninsured patients, and the role of primary health care in China's reform.
Scientists at Sanford Burnham Prebys Medical Discovery Institute used publicly available cancer databases to identify novel cancer driver genes associated with cancer progression. The study found 71 previously unrecognized interfaces in proteins that may serve as new predictive markers or drug targets.
Biosimilars are complex proteins that provide therapeutically equivalent alternatives to expensive biologics, reducing treatment costs in rheumatology and other fields. The introduction of biosimilars into clinical practice requires careful management to ensure patient safety and efficacy.
A small phase I clinical trial found that an FDA-approved leukemia drug improved cognition, motor skills, and non-motor function in patients with Parkinson's disease and Lewy body dementia. The drug, nilotinib, also reduced toxic proteins linked to disease progression.